Merkel Cell Carcinoma Treatment Options
Merkel cell carcinoma (MCC) is a rare yet aggressive form of skin cancer that requires a comprehensive and individualized approach to treatment. Understanding the various therapeutic strategies available is crucial for patients and their caregivers navigating this complex diagnosis.
Key Takeaways
- Merkel cell carcinoma treatment often begins with surgery and may include radiation therapy for local and regional control.
- Immunotherapy, particularly checkpoint inhibitors, has transformed the management of advanced MCC, offering durable responses for many patients; avelumab was the first checkpoint inhibitor approved specifically for metastatic MCC.
- Chemotherapy is typically reserved for advanced disease when other options are not suitable or effective, playing a supportive role.
- Treatment planning is highly individualized, guided by accurate staging, risk assessment, and a multidisciplinary team approach.
- Participation in clinical trials offers access to new treatments for Merkel cell carcinoma and contributes to ongoing research efforts.
Surgical and Radiation Therapy for Merkel Cell Carcinoma
The initial approach to Merkel cell carcinoma treatment options frequently involves surgical removal of the primary tumor, often followed by radiation therapy. These modalities are critical for achieving local and regional disease control.
Primary Tumor Excision
Surgical excision, known as wide local excision, is typically the first step for localized MCC. The goal is to remove the tumor along with a margin of healthy tissue around it — excision margins of roughly 1 to 2 centimeters are commonly used — to reduce the risk of recurrence while trying to preserve nearby function and appearance. According to the National Cancer Institute, no definitive data show that very wide margins improve overall survival, although some evidence suggests that wider margins can improve local control of the tumor. This foundational step is a key part of effective Merkel cell carcinoma treatment.
Regional Lymph Node Management
Given MCC’s strong tendency to spread to regional lymph nodes, their assessment is a vital part of treatment. A sentinel lymph node biopsy is commonly performed to check whether the cancer has reached the nearest lymph nodes, even if they feel normal on examination. If the biopsy is positive, a lymph node dissection may be recommended, or radiation therapy to the lymph node area might be considered instead. Radiation therapy is also frequently used after surgery, particularly for larger tumors, margins that could not be fully cleared, or lymph node involvement, to help lower the risk of local recurrence. Some research has found that combining radiation with surgery lowers the chance of the cancer coming back nearby, compared with surgery by itself, though not every study has shown the same benefit, so this decision is made on a case-by-case basis with the care team.
Immunotherapy and Targeted Therapies for MCC
In recent years, immunotherapy has transformed the landscape of Merkel cell carcinoma treatment, particularly for advanced or metastatic disease. These therapies work by harnessing a patient’s own immune defenses against cancer cells.
Checkpoint Inhibitors
Checkpoint inhibitors are a cornerstone of modern MCC therapy. These drugs, known as PD-1 or PD-L1 inhibitors, work by blocking signals that stop immune cells from recognizing and destroying cancer cells; three of them — avelumab, pembrolizumab, and retifanlimab — are approved by the FDA specifically for MCC. By releasing these immune “brakes,” the body can more effectively recognize and destroy MCC cells, and clinical trials have shown meaningful, often durable responses, making checkpoint inhibitors the preferred initial systemic treatment for most patients with advanced disease. Avelumab was the first of the three to receive FDA approval, in 2017, for adults and adolescents with metastatic MCC regardless of prior chemotherapy; in the trial that supported that approval, roughly a third of previously treated patients responded to the drug, about one in ten had a complete response, and roughly two-thirds of those responses lasted a year or longer.
Emerging Targeted Drugs
Beyond checkpoint inhibitors, research continues into other targeted therapies aimed at the molecular pathways involved in MCC growth. While not yet as established as immunotherapy, these investigational approaches include combinations with existing drugs and therapies targeting features found in a subset of MCC tumors, including tumors not linked to the Merkel cell polyomavirus. These strategies aim to offer more personalized options, especially for patients who do not respond to or cannot tolerate immunotherapy, and are being evaluated in ongoing clinical trials rather than used as standard care today.
Chemotherapy in Merkel Cell Carcinoma Management
While immunotherapy has largely superseded chemotherapy as the preferred first-line treatment for advanced MCC, chemotherapy still holds a specific role in certain clinical scenarios.
Role in Advanced Disease
Chemotherapy is typically considered for patients with advanced or metastatic MCC who are not candidates for immunotherapy or whose disease has progressed despite it. It can provide rapid, though often temporary, tumor shrinkage and symptom relief. Its effectiveness tends to be less durable than immunotherapy, current evidence has not shown that it leads to long-term disease control, and it is associated with a broader range of side effects. For these reasons, chemotherapy is not usually the first recommendation for newly diagnosed advanced MCC, but rather a valuable alternative or follow-up option.
Common Regimens and Side Effects
Because MCC shares biological features with small cell lung cancer, chemotherapy regimens for MCC are often modeled on those used for that disease — most often a platinum-based drug such as carboplatin or cisplatin combined with etoposide. These regimens aim to kill rapidly dividing cancer cells throughout the body, but they also affect healthy rapidly dividing cells, which can lead to side effects such as:
- Nausea and vomiting
- Fatigue
- Hair loss (alopecia)
- Bone marrow suppression (leading to anemia, increased infection risk, and bleeding)
- Peripheral neuropathy (nerve damage)
The choice of regimen depends on the patient’s overall health, kidney function, and prior treatments. Managing these side effects is an important part of the overall Merkel cell carcinoma treatment plan.
Treatment Planning and Guidelines for MCC
Effective management of MCC relies on careful planning, guided by comprehensive diagnostic information and established clinical evidence.
Staging and Risk Assessment
Accurate staging is central to determining the most appropriate Merkel cell carcinoma treatment plan. The American Joint Committee on Cancer TNM (Tumor, Node, Metastasis) staging system is used to classify the extent of the disease, based on the primary tumor size (T), involvement of regional lymph nodes (N), and presence of distant metastasis (M). Factors such as tumor size, depth of invasion, lymphovascular invasion, and the patient’s immune status are also considered for risk assessment. High-risk features often lead to more aggressive treatment strategies, including adjuvant radiation or systemic therapy, aimed at improving outcomes.
Multidisciplinary Care Approach
Given the complexity and aggressiveness of MCC, a multidisciplinary team approach is essential for well-coordinated patient care. This team typically includes:
- Dermatologists or surgical oncologists for primary tumor management.
- Radiation oncologists for adjuvant or palliative radiation therapy.
- Medical oncologists specializing in systemic therapies like immunotherapy and chemotherapy.
- Pathologists for accurate diagnosis and staging.
- Radiologists for imaging studies.
This collaborative approach ensures that all aspects of the disease are considered, leading to a coordinated treatment plan. Regular tumor board discussions allow specialists to collectively decide which treatment approach best fits each patient’s individual situation, in line with current Merkel cell carcinoma treatment guidelines.
Emerging Treatments and Clinical Trials for MCC
The field of oncology is constantly evolving, and MCC treatment is no exception. Ongoing research and clinical trials are vital for discovering and validating new therapeutic strategies.
Investigational Therapies
Beyond currently approved immunotherapies, several investigational therapies are under evaluation, including novel drug combinations, other classes of immunotherapy such as adoptive cell therapies, and approaches targeting unique features of MCC biology. Some trials are also exploring vaccines designed to stimulate an immune response against MCC-specific antigens. These approaches aim to improve response rates, prolong survival, and reduce side effects, continually expanding the range of treatment options being studied for MCC.
Benefits of Clinical Trial Participation
Participating in a clinical trial offers several potential benefits for patients with MCC. It provides access to new treatments for Merkel cell carcinoma that are not yet widely available, often at no direct cost. Patients receive close monitoring and expert medical care from specialists, and contributing to clinical research helps advance scientific understanding of MCC, potentially leading to improved treatments for future patients. Anyone considering this route should talk with their oncology team about whether they qualify and whether a particular trial fits their situation.
Frequently Asked Questions
What is the primary goal of Merkel cell carcinoma treatment?
The main aim is to eliminate the cancer, keep it from coming back or spreading, and preserve the patient’s quality of life. For localized disease, treatment is often aimed at a cure through surgery and radiation. For advanced or metastatic MCC, the focus shifts to controlling the disease and managing symptoms, often with immunotherapy.
How do doctors decide on the best treatment plan for MCC?
Doctors weigh several factors, including the cancer’s stage (tumor size, lymph node involvement, and whether it has spread), the patient’s overall health and age, and personal preferences. A multidisciplinary team reviews the diagnostic results and risk factors together to recommend a personalized treatment strategy.
Are there any long-term side effects of Merkel cell carcinoma treatments?
Yes. Surgery can leave scarring or functional limitations, and radiation therapy can cause skin changes, fatigue, or, rarely, a second cancer years later. Immunotherapy is generally well tolerated but can trigger immune-related side effects in other organs that sometimes persist after treatment ends, while chemotherapy’s side effects, such as nerve damage, can also be long-lasting. Regular follow-up and supportive care are important for managing these possible long-term effects.
Sources
